Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?
deadline 2026-11-27
confidence low
tier 4 evidence
44%PolySignal estimate
Resolution criterion
Resolves YES if the FDA publishes an approval (Drugs@FDA or an official Nuvalent press release) for neladalkib in TKI-pretreated, advanced ALK-positive NSCLC on or before 27 November 2026. A complete response letter, a postponement of the PDUFA date, or the absence of a decision count as no. An approval restricted to a narrower prior-treatment subgroup than described counts as no; flag for manual review if unclear.
Verified starting state
NDA accepted with Priority Review, PDUFA date 27 November 2026, based on efficacy data from the ALKOVE-1 trial in TKI-pretreated ALK-positive NSCLC patients. Fourth-generation ALK inhibitor; the mechanism class (ALK inhibition) already has approved drugs (alectinib, lorlatinib). (Nuvalent press release / OncLive, 27 May 2026)
What pushes it up
- The NDA was accepted with Priority Review, indicating the FDA found the application complete and the data potentially significant [tier 4, corroborated by hand-verified state].
- GSK's acquisition of Nuvalent for $10.6bn suggests strong confidence in the asset's commercial and clinical viability [tier 4].
What pushes it down
- The drug is a fourth-generation ALK inhibitor competing in a crowded market with established approved drugs like alectinib and lorlatinib, which may lower the threshold for approval or increase scrutiny on incremental benefit [hand-verified state].
- The provided press articles are all Tier 4 (aggregators/trade press) and do not provide independent Tier 1 or 2 confirmation of the specific efficacy data or regulatory status beyond the hand-verified summary [tier 4].
What would move this number most
Whether the ALKOVE-1 trial data demonstrates sufficient superiority or non-inferiority over existing standard-of-care ALK inhibitors to meet the FDA's efficacy bar, as no specific efficacy metrics were provided in the source list to justify deviating from the 40% base rate.
How this number is built
| Deadline | 2026-11-27 |
| Base rate | 40% |
| Best evidence | tier 4 · 4 article(s) used |
| Independent runs | 40 · 48 (spread 8 pts) |
| Confidence | low |
| Evidence cap | not triggered |
| Last revised | 2026-09-22 00:42 |
| Model | qwen/qwen3.8-27b (Groq) |
Sources consulted